非アルコール性脂肪肝炎バイオマーカーの世界市場レポート 2025年

非アルコール性脂肪肝炎バイオマーカー市場規模は、今後数年間で飛躍的な成長が見込まれます。2029年にはCAGR22.8％で38億6,000万米ドルに成長します。予測期間の成長は、新規治療法の出現、精密医療アプローチの拡大、患者支援イニシアティブ、マルチオミクスデータの統合、患者エンゲージメントの強化に起因すると考えられます。予測期間における世界の動向には、遠隔医療と遠隔モニタリング、革新的な診断プラットフォーム、世界の共同研究、バイオマーカー探索の技術進歩、人工知能（AI）の統合、画像バイオマーカーの取り込みなどが含まれます。

肝臓がんの発生率の増加は、将来的に非アルコール性脂肪肝炎（NASH）バイオマーカー市場の拡大を促進すると予想されます。肝臓がんは肝臓に悪性腫瘍が形成されるもので、肝臓自体から発生するもの（原発性肝がん）、体の他の部位から転移するもの（続発性または転移性肝がん）があります。NASHバイオマーカーは肝がんの早期発見、病勢進行のモニタリング、治療効果の評価に利用され、予後情報を提供すると同時に、侵襲的処置の必要性を減らす可能性があります。例えば、英国を拠点とする非営利団体である世界がん研究基金は、2022年に世界で新たに約866,136人の肝臓がん患者が発生したと報告し、このがんは世界で6番目に多いがんとされました。その結果、肝臓がんの有病率の上昇が非アルコール性脂肪肝炎バイオマーカー市場の成長を後押ししています。

個別化医療に対する需要の高まりが、非アルコール性脂肪肝炎バイオマーカー市場の成長を後押ししています。個別化医療とは、医療上の意思決定、介入、薬物療法を個々の患者に合わせて調整することです。非アルコール性脂肪性肝炎（NASH）バイオマーカーの文脈では、個別化医療は、正確で個別化された診断、個別化された治療戦略の開発、最適化された薬剤選択、治療反応モニタリング、副作用の最小化を促進します。2022年10月のレポートでは、75,000を超える遺伝子検査製品と300を超える個別化医薬品が報告されており、個別化医療に対する需要の高まりとそれが非アルコール性脂肪肝炎バイオマーカー市場を牽引する役割を強調しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界非アルコール性脂肪肝炎バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、制約）
• 最終用途産業の分析
• 世界の非アルコール性脂肪肝炎バイオマーカー市場：成長率分析
• 世界の非アルコール性脂肪肝炎バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の非アルコール性脂肪肝炎バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界非アルコール性脂肪肝炎バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非アルコール性脂肪肝炎バイオマーカー市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝線維症バイオマーカー
• 血清バイオマーカー
• 酸化ストレスバイオマーカー
• アポトーシスバイオマーカー
• その他のタイプ
• 世界の非アルコール性脂肪肝炎バイオマーカー市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高血圧
• 心臓病
• 高血中脂質
• 2型糖尿病
• 肥満
• 世界の非アルコール性脂肪肝炎バイオマーカー市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 調査機関と学術機関
• 診断センター
• 製薬会社と製薬会社と開発調査受託機関（CRO）
• 病院と診療所
• その他の用途
• 世界の非アルコール性脂肪肝炎バイオマーカー市場肝線維症バイオマーカーのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒアルロン酸
• プロコラーゲンIII N末端プロペプチド（PIIINP）
• 線維症-4（FIB-4）インデックス
• 世界の非アルコール性脂肪肝炎バイオマーカー市場血清バイオマーカーの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アラニンアミノトランスフェラーゼ（ALT）
• アスパラギン酸アミノトランスフェラーゼ（AST）
• アディポネクチン
• 世界の非アルコール性脂肪肝炎バイオマーカー市場酸化ストレスバイオマーカーのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• マロンジアルデヒド（MDA）
• 8-イソプロスタン
• 高度酸化タンパク質製品（AOPP）
• 世界の非アルコール性脂肪肝炎バイオマーカー市場アポトーシスバイオマーカーの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カスパーゼ3
• シトクロムc
• 肝抑制タンパク質（LIP）
• 世界の非アルコール性脂肪肝炎バイオマーカー市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• メタボロミクスバイオマーカー
• 遺伝子バイオマーカー
• 炎症バイオマーカー

第7章 地域別・国別分析

• 世界の非アルコール性脂肪肝炎バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の非アルコール性脂肪肝炎バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非アルコール性脂肪肝炎バイオマーカー市場：競合情勢
• 非アルコール性脂肪肝炎バイオマーカー市場：企業プロファイル
  • Genfit SA Overview, Products and Services, Strategy and Financial Analysis
  • Prometheus Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Siemens Medical Solutions USA Inc. Overview, Products and Services, Strategy and Financial Analysis
  • BioPredictive Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca Plc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Bristol-Myers Squibb Company
• NGM Biopharmaceuticals Inc.
• Gilead Sciences Inc.
• Perspectum Diagnostics Ltd.
• One Way Liver SL
• Enterome SA
• Echosens SA
• Cisbio Bioassays SAS
• Celerion Inc.
• Boehringer Ingelheim GmbH Inc.
• Exalenz Bioscience Ltd.
• Novartis AG

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非アルコール性脂肪肝炎バイオマーカー市場2029：新たな機会を提供する国
• 非アルコール性脂肪肝炎バイオマーカー市場2029：新たな機会を提供するセグメント
• 非アルコール性脂肪肝炎バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation and damage resulting from the accumulation of fat in the liver. NASH biomarkers serve as diagnostic tools to evaluate the severity of non-alcoholic steatohepatitis and assess liver damage. This condition can lead to inflammation and damage to liver cells, potentially causing cirrhosis (liver scarring) and liver failure. Biomarkers, in this context, are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.

The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.36 billion in 2024 to $1.7 billion in 2025 at a compound annual growth rate (CAGR) of 24.8%. The growth in the historic period can be attributed to diabetes and metabolic syndrome, awareness and screening programs, liver biopsy limitations, regulatory support, shift towards personalized medicine, clinical trials in NASH.

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.86 billion in 2029 at a compound annual growth rate (CAGR) of 22.8%. The growth in the forecast period can be attributed to emergence of novel therapies, expansion of precision medicine approaches, patient advocacy initiatives, integration of multi-omics data, enhanced patient engagement. Major trends in the forecast period include telemedicine and remote monitoring, innovative diagnostic platforms, global collaborations in research, technological advancements in biomarker discovery, integration of artificial intelligence (AI), inclusion of imaging biomarkers.

The increasing incidence of liver cancer is anticipated to drive the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers market in the future. Liver cancer involves the formation of malignant tumors in the liver, which can originate in the liver itself (primary liver cancer) or spread from other areas of the body (secondary or metastatic liver cancer). NASH biomarkers are utilized in liver cancer for early detection, monitoring disease progression, and evaluating treatment response, providing prognostic information while potentially reducing the necessity for invasive procedures. For example, in 2022, the World Cancer Research Fund, a UK-based non-profit organization, reported approximately 866,136 new liver cancer cases globally, ranking it as the sixth most common cancer worldwide. As a result, the rising prevalence of liver cancer is fueling the growth of the non-alcoholic steatohepatitis biomarkers market.

The increasing demand for personalized medicine is poised to fuel the growth of the non-alcoholic steatohepatitis biomarkers market. Personalized medicine involves tailoring medical decisions, interventions, and drug therapies to individual patients. In the context of non-alcoholic steatohepatitis (NASH) biomarkers, personalized medicine facilitates precise and individualized diagnosis, the development of tailored treatment strategies, optimized drug selection, treatment response monitoring, and minimization of adverse effects. Reports from October 2022 indicate over 75,000 genetic testing products and 300 personalized medicines, highlighting the growing demand for personalized medicine and its role in driving the non-alcoholic steatohepatitis biomarkers market.

Technological advancements have emerged as a prominent trend in the non-alcoholic steatohepatitis biomarkers market, with major companies focusing on innovative solutions to enhance their market position. In October 2022, GENFIT and LabCorp entered a five-year exclusive licensing deal for GENFIT's NIS4 technology, a multi-biomarker-based algorithm designed to identify patients at risk of non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis. LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada. This partnership aims to provide widespread access to healthcare professionals, demonstrating the importance of technological advancements in driving the non-alcoholic steatohepatitis biomarkers market.

Key companies in the non-alcoholic steatohepatitis (NASH) biomarkers market are concentrating on implementing Enhanced Liver Fibrosis (ELF) tests to enhance the diagnosis and monitoring of liver fibrosis, a critical aspect of NASH. The ELF Test is a blood-based diagnostic tool designed to evaluate the prognosis for patients with advanced fibrosis (F3 or F4) resulting from non-alcoholic steatohepatitis, which is a form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation. For instance, in January 2022, Siemens Healthineers, a Germany-based company, introduced the Enhanced Liver Fibrosis (ELF) Test. This test was the first blood test to receive De Novo marketing authorization from the FDA specifically for assessing disease progression in NASH patients. By using a simple blood sample, the ELF Test evaluates three biomarkers linked to liver fibrosis: hyaluronic acid, tissue inhibitor of metalloproteinases 1 (TIMP-1), and aminoterminal propeptide of type III procollagen (P3NP). This method eliminates the need for invasive procedures, such as liver biopsies. The test is widely available through partnerships with Labcorp and Quest Diagnostics, ensuring accessibility for patients and healthcare providers throughout the U.S.

In June 2022, Novo Nordisk A/S partnered with Echosens SA to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise awareness among patients, medical professionals, and other stakeholders. Echosens SA, a France-based manufacturer, specializes in therapeutic monitoring and diagnostic devices.

Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Hepatic Fibrosis Biomarkers; Serum Biomarkers; Oxidative Stress Biomarkers; Apoptosis Biomarkers; Other Types
• 2) By Disease: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
• 3) By End Use: Research Institutes And Academics; Diagnostic Centers; Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs); Hospitals And Clinics; Other End-Uses
• Subsegments:
• 1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid; Procollagen III N-terminal Propeptide (PIIINP); Fibrosis-4 (FIB-4) Index
• 2) By Serum Biomarkers: Alanine Aminotransferase (ALT); Aspartate Aminotransferase (AST); Adiponectin
• 3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA); 8-Isoprostane; Advanced Oxidation Protein Products (AOPP)
• 4) By Apoptosis Biomarkers: Caspase-3; Cytochrome c; Liver Inhibitory Protein (LIP)
• 5) By Other Types: Metabolomic Biomarkers; Genetic Biomarkers; Inflammatory Biomarkers
• Companies Mentioned: Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Alcoholic Steatohepatitis Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market Growth Rate Analysis
• 5.4. Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Alcoholic Steatohepatitis Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Alcoholic Steatohepatitis Biomarkers Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatic Fibrosis Biomarkers
• Serum Biomarkers
• Oxidative Stress Biomarkers
• Apoptosis Biomarkers
• Other Types
• 6.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertension
• Heart Disease
• High Blood Lipid
• Type 2 Diabetes
• Obesity
• 6.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research Institutes And Academics
• Diagnostic Centres
• Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs)
• Hospitals And Clinics
• Other End-Uses
• 6.4. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Hepatic Fibrosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hyaluronic Acid
• Procollagen III N-terminal Propeptide (PIIINP)
• Fibrosis-4 (FIB-4) Index
• 6.5. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Serum Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alanine Aminotransferase (ALT)
• Aspartate Aminotransferase (AST)
• Adiponectin
• 6.6. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Oxidative Stress Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Malondialdehyde (MDA)
• 8-Isoprostane
• Advanced Oxidation Protein Products (AOPP)
• 6.7. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Apoptosis Biomarkers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Caspase-3
• Cytochrome c
• Liver Inhibitory Protein (LIP)
• 6.8. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metabolomic Biomarkers
• Genetic Biomarkers
• Inflammatory Biomarkers

7. Non-Alcoholic Steatohepatitis Biomarkers Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis Biomarkers Market

• 9.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis Biomarkers Market

• 10.1. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Biomarkers Market

• 11.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Biomarkers Market

• 12.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Biomarkers Market

• 16.1. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Biomarkers Market

• 17.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis Biomarkers Market

• 18.1. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Biomarkers Market

• 19.1. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Biomarkers Market

• 20.1. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Biomarkers Market

• 22.1. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Biomarkers Market

• 23.1. North America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Biomarkers Market

• 24.1. USA Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Biomarkers Market

• 25.1. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Biomarkers Market

• 26.1. South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

• 29.1. Africa Non-Alcoholic Steatohepatitis Biomarkers Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
  • 30.2.1. Genfit SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Prometheus Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens Medical Solutions USA Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioPredictive Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Quest Diagnostics Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis Biomarkers Market Other Major And Innovative Companies

• 31.1. AstraZeneca Plc.
• 31.2. Laboratory Corporation of America Holdings
• 31.3. Pfizer Inc.
• 31.4. Bristol-Myers Squibb Company
• 31.5. NGM Biopharmaceuticals Inc.
• 31.6. Gilead Sciences Inc.
• 31.7. Perspectum Diagnostics Ltd.
• 31.8. One Way Liver SL
• 31.9. Enterome SA
• 31.10. Echosens SA
• 31.11. Cisbio Bioassays SAS
• 31.12. Celerion Inc.
• 31.13. Boehringer Ingelheim GmbH Inc.
• 31.14. Exalenz Bioscience Ltd.
• 31.15. Novartis AG

32. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis Biomarkers Market

35. Non-Alcoholic Steatohepatitis Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Alcoholic Steatohepatitis Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer